| 林贵玲,徐丛剑.卵巢癌铂类耐药标志物的研究进展[J].中国肿瘤,2018,27(12):944-948. |
| 卵巢癌铂类耐药标志物的研究进展 |
| Research Progress on Markers of Platinum Resistance in Ovarian Cancer |
| 投稿时间：2018-07-06 |
| DOI：10.11735/j.issn.1004-0242.2018.12.A009 |
|
 |
| 中文关键词: 卵巢肿瘤 化疗耐药 铂类耐药 生物标志物 |
| 英文关键词:ovarian neoplasms chemoresistance platinum resistance biomarker |
| 基金项目:国家重点研发计划（2016YFC1303100） |
|
| 摘要点击次数: 1846 |
| 全文下载次数: 445 |
| 中文摘要: |
| 摘 要：卵巢癌是女性三大恶性肿瘤之一，其死亡率位于妇科癌症之首。铂类联合紫杉醇是卵巢癌术后一线化疗方案，但约75%晚期患者对铂类药物耐药。铂类耐药标志物能预测患者对铂类药物的反应，指导卵巢癌患者治疗药物的选择。本篇综述按靶前、靶点、靶后和靶外标志物四个方面对近几年的卵巢癌铂类耐药标志物的研究成果进行归纳并简单阐述其相应的耐药机制。 |
| 英文摘要: |
| Abstract：Ovarian cancer is one of the most common malignancies in women and its mortality rate is the highest among gynecological cancers. Platinum and paclitaxel combination chemotherapy is the first-line postoperative regimen for ovarian cancer，but about 75% of advanced patients are resistant to platinum drugs. Drug resistance markers can predict the response to platinum-based chemotherapy and will contribute to selecting therapeutic drugs for patients with ovarian cancer. This review summarizes the researches on platinum-resistant markers of ovarian cancer in recent years，including pre-target，on-target，post-target and off-target markers，and also describes the corresponding mechanisms briefly. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |